Connection

Oliver Cornely to Aged, 80 and over

Back to Details
This is a "connection" page, showing publications Oliver Cornely has written about Aged, 80 and over.
Oliver Cornely
Connection Strength
0.196
Aged, 80 and over
  1. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses. Eur J Clin Microbiol Infect Dis. 2019 Jun; 38(6):1187-1194.
    View in: PubMed
    Score: 0.023
  2. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged =60 years (EXTEND): analysis of cost-effectiveness. J Antimicrob Chemother. 2018 09 01; 73(9):2529-2539.
    View in: PubMed
    Score: 0.022
  3. Isavuconazole for treatment of rare invasive fungal diseases. Mycoses. 2018 Aug; 61(8):518-533.
    View in: PubMed
    Score: 0.022
  4. How to prophylax against invasive fungal infections in adult ALL? An unmet need. Mycoses. 2018 Sep; 61(9):646-649.
    View in: PubMed
    Score: 0.022
  5. Analyzing candidemia guideline adherence identifies opportunities for antifungal stewardship. Eur J Clin Microbiol Infect Dis. 2018 Aug; 37(8):1563-1571.
    View in: PubMed
    Score: 0.022
  6. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. J Antimicrob Chemother. 2017 Dec 01; 72(12):3406-3413.
    View in: PubMed
    Score: 0.021
  7. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. J Antimicrob Chemother. 2017 08 01; 72(8):2359-2367.
    View in: PubMed
    Score: 0.020
  8. ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. Mycoses. 2021 Sep; 64(9):1028-1037.
    View in: PubMed
    Score: 0.007
  9. Analysis of IgM, IgA, and IgG isotype antibodies Directed against SARS-CoV-2 spike glycoprotein and ORF8 in the course of COVID-19. Sci Rep. 2021 04 26; 11(1):8920.
    View in: PubMed
    Score: 0.007
  10. Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system. Med Mycol. 2020 Jun 01; 58(4):417-424.
    View in: PubMed
    Score: 0.006
  11. Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials. Lancet Infect Dis. 2019 03; 19(3):265-274.
    View in: PubMed
    Score: 0.006
  12. Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy. Int J Antimicrob Agents. 2018 Nov; 52(5):706-712.
    View in: PubMed
    Score: 0.005
  13. A Comparison of Aspergillus and Mucorales PCR Testing of Different Bronchoalveolar Lavage Fluid Fractions from Patients with Suspected Invasive Pulmonary Fungal Disease. J Clin Microbiol. 2018 02; 56(2).
    View in: PubMed
    Score: 0.005
  14. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. Lancet Infect Dis. 2018 03; 18(3):296-307.
    View in: PubMed
    Score: 0.005
  15. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. N Engl J Med. 2017 01 26; 376(4):305-317.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.